Home

verlassen Informieren Tasche act 1004 1239 Nord Teilen Bewunderung

Project Overview
Project Overview

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry

FA181705 | 2178049-58-4 | ACT 1004-1239 | Biosynth
FA181705 | 2178049-58-4 | ACT 1004-1239 | Biosynth

ACT-1004-1239 | CXCR Antagonist | MedChemExpress
ACT-1004-1239 | CXCR Antagonist | MedChemExpress

ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - Pouzol - 2021 - The FASEB Journal - Wiley Online Library
ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - Pouzol - 2021 - The FASEB Journal - Wiley Online Library

Frontiers | Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
Frontiers | Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

Effects of Small Molecule Ligands on ACKR3 Receptors | Molecular Pharmacology
Effects of Small Molecule Ligands on ACKR3 Receptors | Molecular Pharmacology

Treatment with ACT-1004-1239 dose-dependently increases plasma CXCL11... | Download Scientific Diagram
Treatment with ACT-1004-1239 dose-dependently increases plasma CXCL11... | Download Scientific Diagram

2178049-58-4 | ACT-1004-1239| ACT1004-1239; ACT 1004-1239; ACT-10041239; ACT -1004 1239; ACT10041239; ACT 1004 1239|BioChemPartner
2178049-58-4 | ACT-1004-1239| ACT1004-1239; ACT 1004-1239; ACT-10041239; ACT -1004 1239; ACT10041239; ACT 1004 1239|BioChemPartner

Idorsia Stock: Positive Catalyst Coming Very Soon (OTCMKTS:IDRSF) | Seeking Alpha
Idorsia Stock: Positive Catalyst Coming Very Soon (OTCMKTS:IDRSF) | Seeking Alpha

Idorsia: Heading Towards Profitability Faster Than Expected (OTCMKTS:IDRSF) | Seeking Alpha
Idorsia: Heading Towards Profitability Faster Than Expected (OTCMKTS:IDRSF) | Seeking Alpha

Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment
Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment

ACT-1004-1239 |2178049-58-4 |Chemokine Receptor (CCR and CXCR)|HmoBio.com
ACT-1004-1239 |2178049-58-4 |Chemokine Receptor (CCR and CXCR)|HmoBio.com

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT- 1004-1239 | Journal of Medicinal Chemistry

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans - ScienceDirect
Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans - ScienceDirect

ACT-1004-1239 [2178049-58-4] CXCR7 Antagonist | Glixxlabs.com High Quality Supplier
ACT-1004-1239 [2178049-58-4] CXCR7 Antagonist | Glixxlabs.com High Quality Supplier

ACT-1004-1239 | CAS#2178049-58-4 | Insurmountable antagonist | MedKoo
ACT-1004-1239 | CAS#2178049-58-4 | Insurmountable antagonist | MedKoo

ACT-1004-1239 and CXCL12 plasma concentration-time profiles and... | Download Scientific Diagram
ACT-1004-1239 and CXCL12 plasma concentration-time profiles and... | Download Scientific Diagram

Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment
Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment

Proposed metabolic pathways of ACT-1004-1239 in humans. | Download Scientific Diagram
Proposed metabolic pathways of ACT-1004-1239 in humans. | Download Scientific Diagram

PDF) ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases
PDF) ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases